University of Nantes Angers Le Mans researchers have used mannosides to directly target adherent-invasive Escherichia coli, which cause intestinal inflammation in Crohn's disease. The team is planning to test this alternative to standard-of-care TNF-lowering therapies in a mouse model for chronic CD.